- Mirogabalin besylate
-
- $0.00 / 1KG
-
2022-09-08
- CAS:1138245-21-2
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1tone
|
| | Mirogabalin besylate Basic information |
| Product Name: | Mirogabalin besylate | | Synonyms: | Mirogabalin besylate;Mirogabalin besylat;MIROGABALIN BENZENESULFONIC ACID;((1R,5S,6S)-6-(carboxymethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)methanaminium benzenesulfonate;[(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0] hept-3-en-6-yl]acetic acid benzenesulfonate;2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid compound with benzenesulfonic acid (1:1);Mirogabalin Besylate 10928;Mirogabalin besylate (DS 5565 besylate) | | CAS: | 1138245-21-2 | | MF: | C18H25NO5S | | MW: | 367.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1138245-21-2.mol |  |
| | Mirogabalin besylate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (340.17 mM) | | form | Solid | | color | White to off-white | | InChI | InChI=1/C12H19NO2.C6H6O3S/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8;7-10(8,9)6-4-2-1-3-5-6/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15);1-5H,(H,7,8,9)/t9-,10-,12-;/s3 | | InChIKey | OKJXJRVWXYRSAN-QWGAVYBYNA-N | | SMILES | S(C1C=CC=CC=1)(O)(=O)=O.C([C@]1(C[C@@]2([H])CC(CC)=C[C@@]12[H])CN)C(=O)O |&1:11,13,20,r| |
| | Mirogabalin besylate Usage And Synthesis |
| Description | Mirogabalin besylate (mirogabalin, Tarlige) is a gabapentinoid therapy developed by Daiichi Sankyo, which is approved in Japan for the treatment of postherpetic neuralgia and painful diabetic peripheral neuropathy. Mirogabalin has a potent pain-modulating effect with a unique high affinity and prolonged dissociation rate for the a2delta-1 subunit of voltage-gated calcium (Ca2+) channels (VGCCs) on the dorsal root ganglion resulting in more sustained analgesia compared with traditional gabapentinoids[1].
| | Uses | Mirogabalin besylate is an oral gabapentin analogue for the treatment of peripheral neuralgia (PNP), including diabetic PNP and postherpetic neuralgia. The drug has been approved in Japan for the treatment of PNP and has not yet received FDA approval. | | Side effects | Mirogabalin has a superior adverse events (AEs) profile due to a rapid dissociation from the a2delta-2 subunit of VGCCs potentially implicated in central nervous system-specific AEs. The most common AEs for mirogabalin are dizziness (approximately 8-16%), somnolence (approximately 6-24%) and headache (approximately 6-14%), with a lower incidence of constipation, nausea, diarrhea, vomiting, edema, fatigue and weight gain[1]. | | References |
[1] J Burgess. “Mirogabalin besylate in the treatment of neuropathic pain.” Drugs of today 56 2 (2020): 135–149.
|
| | Mirogabalin besylate Preparation Products And Raw materials |
|